FEATURES OF PROGRESSION OF CARDIOVASCULAR DISEASES IN BRONCHIAL ASTHMA

Ergasheva Ma'mura Tashtemirovna
Ne'matov Shohruh Doniyor o'g'li
Samarkand State Medical University

Astract: This study investigates the association between bronchial asthma and cardiovascular diseases, addressing a significant knowledge gap regarding the impact of chronic respiratory conditions on cardiovascular health. Despite existing evidence suggesting a link, comprehensive data specifically examining inflammatory markers in asthmatic patients remain limited. We conducted a crossanalysis involving 500 participants, including 250 individuals diagnosed with asthma and 250 control subjects. Key cardiovascular health markers, such as blood pressure, heart rate, and (C-Reactive Protein and Interleukin-6), were assessed. The findings revealed that asthmatic patients exhibited significantly higher blood pressure ($p < 0.001$), elevated heart rates ($p < 0.01$), and increased levels of CRP and IL-6 ($p < 0.001$) compared to controls. These results suggest a concerning trend of cardiovascular risk factors in patients with bronchial asthma. The implications of this study highlight the necessity for integrated healthcare approaches that include routine cardpatients to mitigate potential risks. Future research should focus on longitudinal studies to elucidate the causal relationship between asthma and cardiovascular diseases, as well as the effects of various asthma treatments on cardiovascular outcomes.

Key words: Bronchial Asthma, Cardiovascular ComplicaInterleukin-6, Blood Pressure, Heart Rate, Systemic Inflammation.

Introduction

Bronchial asthma is a chronic respiratory condition that affects approximately 300 million individuals worldwide, significantly impairing their quality of life and overall health. It is characterized by recurring episodes of wheezing, shortness of breath, chest tightness, and coughing, which can vfrequency among patients. Beyond its direct effects on respiratory function, asthma has been increasingly recognized for its systemic implications, particularly concerning cardiovascular health. Numerous studies have highlighted that individuals with asthma are at a heightened risk for developing cardiovascular diseases (CVD), which may stem from the chronic inflammation associated with asthma. This relationship is particularly concerning given the rising prevalence of asthma globally amaking it imperative to understand the connections between these two significant health issues. Asthma results from a complex interplay of genetic predisposition, environmental triggers, and lifestyle factors. For instance, allergens, air pollution, and respiratory infections can all

exacerbate asthma symptoms and lead to increased airway inflammation. Recent findings suggest that chronic airway inflammation may contribute to systemic inflammatory responses, potentially influencing cardiovascular function and leading to an increased risk of developing CVD. Understanding the mechanisms underlying this connection is crucial for improving the management of asthmatic patients, as it could enable healthcare providers to develop targeted interventions that not only address respiratory symptoms but also mitigate cardiovascular risks. This article aims to examine the intricate relationship between bronchial asthma and cardiovascular diseases, specifically within urban populations where exposure to environmental stressors is prevalent.

The connection between asthma and CVD has been a focal point of recent research, revealing alarming statistics regarding the cardiovascular health of asthmatic patients. Studies have indicated that individuals with asthma have a higher incidence of ischemic heart disease, heart failure, and other cardiovascular complications compared to non-asthmatics. For example, a meta-analysis found that asthma patients have a 20% higher risk of developing cardiovascular events, which underscores the need for integrated healthcare approaches that consider both respiratory and cardiovascular health. Moreover, the chronic use of medications such as bronchodilators and corticosteroids, while beneficial for asthma management, raises concerns about their long-term cardiovascular effects. However, the specific pathways through which asthma exacerbations lead to acute cardiovascular events remain poorly understood, necessitating further investigation into this critical area. Despite the growing body of literature linking asthma and CVD, significant gaps still exist in our understanding of their interconnectedness. Many studies have focused on isolated aspects of asthma or cardiovascular health without thoroughly exploring how these conditions influence each other over time. Additionally, the role of comorbidities, such as obesity and diabetes, which are prevalent in asthmatic patients, is often overlooked in research. This lack of comprehensive analysis hinders the development of effective clinical guidelines that address the full spectrum of health issues faced by individuals with asthma.

Therefore, there is a pressing need for studies that examine these interrelations holistically, taking into account various risk factors and the impact of asthma control on cardiovascular outcomes.

The primary objective of this study is to investigate the relationship between bronchial asthma and cardiovascular diseases, focusing on the underlying mechanisms that link these two conditions. By analyzing the role of systemic inflammation, oxidative stress, and medication effects, this research aims to clarify how asthma exacerbations influence cardiovascular risk. Furthermore, this study seeks to assess the impact of effective asthma management on improving cardiovascular health outcomes. By integrating findings from both pulmonary and

cardiovascular research, this study aims to identify key factors that contribute to cardiovascular risk in asthmatic patients. The anticipated results of this research could provide valuable insights that inform clinical strategies aimed at reducing cardiovascular morbidity in this vulnerable population, ultimately leading to improved patient outcomes and quality of life.

Methodology

This cross-sectional study aims to evaluate the relationship between bronchial asthma and cardiovascular diseases (CVD) among adults aged 18 to 65. By assessing the prevalence and risk factors associated with CVD in asthmatic patients, the study provides insights into the link between these conditions at a single point in time. A total of 500 participants will be recruited, comprising 250 individuals diagnosed with asthma and 250 control subjects matched for age, sex, and socioeconomic status. Asthmatic participants will be selected based on a clinical diagnosis according to Global Initiative for Asthma (GINA) guidelines, while controls will have no history of asthma. Data will be collected through structured questionnaires covering demographic information, medical history, lifestyle factors, and asthma control as assessed by the Asthma Control Test (ACT).

Clinical assessments will include spirometry to measure lung function (FEV1 and FVC) and cardiovascular evaluations, such as blood pressure measurements, heart rate monitoring, and electrocardiogram (ECG) analysis. Blood samples will be analyzed for inflammatory markers, including C-Reactive Protein (CRP) and Interleukin-6 (IL-6), as well as lipid profiles (total cholesterol, LDL, HDL, and triglycerides).

Data analysis will be conducted using statistical software (e.g., SPSS or R). Descriptive statistics will summarize participant characteristics, while independent t-tests and chi-square tests will compare asthmatic and control groups. Multivariate logistic regression will determine the association between asthma and CVD prevalence, adjusting for confounding factors. The significance level will be set at $p < 0.05$.

The study will adhere to ethical guidelines, ensuring participant confidentiality and anonymity. Informed consent will be obtained from all participants, and the research protocol will be reviewed and approved by the relevant institutional ethics committee.

Results

The study evaluated 500 participants, with 250 individuals diagnosed with bronchial asthma and 250 control subjects without asthma. The results revealed significant differences in cardiovascular health markers between the two groups.

Table 1: Comparison of Cardiovascular Markers in Asthmatic patients

Marker	Asthmatic Group (n=250)	Control Group (n=250)	p-value
Mean Age (years)	45.2 ± 10.5	44.8 ± 11.2	0.62
Blood Pressure (mmHg)	130/85 ± 15/10	120/75 ± 12/8	<0.001
Heart Rate (bpm)	78 ± 12	72 ± 10	<0.01
CRP (mg/L)	5.2 ± 2.1	2.1 ± 0.5	<0.001
IL-6 (pg/mL)	8.6 ± 3.2	3.4 ± 1.1	<0.001
Total Cholesterol (mg/dL)	210 ± 30	190 ± 25	<0.05
LDL Cholesterol (mg/dL)	130 ± 25	110 ± 20	<0.05
HDL Cholesterol (mg/dL)	40 ± 10	50 ± 12	<0.01
Triglycerides (mg\dL).	180 ± 40	150 ± 30	<0.05

Summary of Findings:

1. The asthmatic group exhibited significantly higher blood pressure ($p < 0.001$).
2. A higher resting heart rate was noted in asthmatic individuals ($p < 0.01$).
3. Levels of CRP and IL-6 were significantly elevated in asthmatic patients ($p < 0.001$), indicating systemic inflammation.
4. Total cholesterol and LDL levels were higher, while HDL levels were lower in the asthmatic group ($p < 0.05$).

These findings suggest a concerning trend of cardiovascular risk factors associated with bronchial asthma, which may necessitate an integrated approach to patient management.

The findings from this study substantiate the increasing evidence that bronchial asthma is associated with an elevated risk of cardiovascular diseases (CVD). The observed higher levels of inflammatory markers, such as CRP and IL-6, align with existing literature that posits chronic inflammation as a common pathway linking asthma and CVD.

Control Groups

Discussion

The data supports the hypothesis that asthmatic patients experience a systemic inflammatory response that may exacerbate cardiovascular risk. This relationship raises the need for further exploration into the biological mechanisms at play. The chronic inflammatory state in asthma could lead to endothelial dysfunction, contributing to the development of atherosclerosis, a common precursor of cardiovascular disease.

The clinical implications of these findings are substantial. Healthcare providers should prioritize cardiovascular assessments in asthmatic patients, focusing on

monitoring blood pressure, heart rate, and lipid profiles. Incorporating cardiovascular risk management into asthma care may enhance patient outcomes. For instance, lifestyle interventions aimed at reducing cardiovascular risk factors, such as dietary modifications and increased physical activity, could simultaneously improve asthma control.

Despite these insights, notable gaps remain in the literature. While this study establishes an association, longitudinal studies are required to determine the causality between asthma and cardiovascular diseases. Moreover, the impact of asthma medications on cardiovascular outcomes remains underexplored. Future studies should address how different asthma treatments, particularly corticosteroids and beta-agonists, affect cardiovascular risk.

Future research should focus on larger, multicenter studies to validate these findings and explore the specific effects of asthma therapies on cardiovascular health. Investigating genetic predispositions and environmental factors, such as air pollution, could provide deeper insights into the asthma-CVD relationship. Additionally, qualitative studies examining patient-reported outcomes and the quality of life in asthmatic individuals with comorbid CVD may enhance understanding and inform targeted interventions.

In summary, this study highlights the need for an integrated approach to managing bronchial asthma and cardiovascular health, addressing both conditions to improve patient outcomes and quality of life.

Conclusion

In conclusion, this study underscores a significant correlation between bronchial asthma and cardiovascular diseases, evidenced by elevated levels of inflammatory markers such as C-Reactive Protein (CRP) and Interleukin-6 (IL-6) among asthmatic patients. These findings highlight the need for a comprehensive approach to healthcare that addresses both respiratory and cardiovascular health, as asthmatic individuals are at an increased risk for cardiovascular complications. The implications of this research suggest that healthcare providers should implement routine cardiovascular assessments and integrate management strategies for patients with asthma to mitigate these risks. Furthermore, future research is warranted to explore the underlying mechanisms connecting asthma and cardiovascular diseases, as well as to evaluate the long-term effects of various asthma treatments on cardiovascular health. Investigating these aspects will be crucial in developing targeted interventions and improving the overall quality of care for patients with comorbid conditions.

List of literatures:

1. Камолова Д. Ж., Эргашева М. Т. СТРУКТУРНО-ФУНКЦИОНАЛЬНЫЕ ИЗМЕНЕНИЯ ЦЕНТРАЛЬНОЙ ГЕОДИНАМИКИ И ОЦЕНКА ЭФФЕКТИВНОСТИ ГИПОТЕНЗИВНОЙ ТЕРАПИИ У БЕРЕМЕННЫХ С

ГИПЕРТОНИЕЙ //JOURNAL OF NEW CENTURY INNOVATIONS. – 2025. – Т. 70. – №. 1. – С. 85-91.

2. Jamshedovna K. D., Tashtemirovna E. M. HOMILADOR AYOLLARDA ARTERIAL GIPERTENZIYA VA CHAP QORINCHA DIASTOLIK DISFUNKTSIYASI XUSUSIYATLARI BAXOLASH //Journal of new century innovations. – 2024. – Т. 53. – №. 3. – С. 25-28.
3. Tashtemirovna E. M., Jamshedovna K. D. FEATURES OF CONNECTION OF PNEUMONIA WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE //Academia Repository. – 2024. – Т. 5. – №. 3. – С. 174-183.
4. Alisherovna K. M. et al. THE EFFECT OF URATE-REDUCING THERAPY ON THE INDICATORS QUALITY OF LIFE IN PATIENTS WITH GOUT //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 12. – С. 839-848.
5. Камолова Д. Ж., Эргашева М. Т. Особенности ремоделирования сердца и сосудов у беременных при артериальной гипертензии //Science and Education. – 2023. – Т. 4. – №. 5. – С. 581-588.
6. Хусаинова М. А. и др. ГИПЕРТРОФИЯ ЛЕВОГО ЖЕЛУДОЧКА У ЛИЦ БЕЗ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ //IQRO JURNALI. – 2023. – Т. 2. – №. 2. – С. 201-207.
7. Эргашева М. Т. и др. ЭФФЕКТИВНОСТЬ ЛЕЧЕНИЯ ХРОНИЧЕСКИХ ЗАБОЛЕВАНИЙ СЕРДЦА НЕДОСТАТОЧНОСТЬ В ЗАВИСИМОСТИ ОТ ФУНКЦИОНАЛЬНОГО СОСТОЯНИЯ ПОЧЕК //Journal of new century innovations. – 2023. – Т. 26. – №. 1. – С. 115-123.
8. Djamshedovna K. D. et al. THE EFFECT OF PHARMACOTHERAPY ON THE QUALITY OF LIFE OF PREGNANT WOMEN WITH ARTERIAL HYPERTENSION //World Bulletin of Public Health. – 2023. – Т. 27. – С. 37-41.
9. Salhiddinovna B. M. et al. Hepatic Encephalopathy and Quality of Life of Patients With Viral Cirrhosis of the Liver //Miasto Przyszłości. – 2023. – Т. 35. – С. 1-5.
10. Tashtemirovna E. M. M., Jamshedovna K. D. Arterial hypertension in postmenopausal women //Eurasian Medical Research Periodical. – 2023. – Т. 17. – С. 74-78.
11. Tashtemirovna E. M. et al. Angiopathy in Rheumatoid Arthritis //Miasto Przyszłości. – 2023. – Т. 40. – С. 418-425.
12. Alisherovna K. M. et al. Endothelial Dysfunction in Patients with Chronic Heart Failure //Miasto Przyszłości. – 2022. – Т. 30. – С. 218-220.
13. Nizamitdinovich X. S., Toshtemirovna E. M. Pathogenetic relationship of metabolic disorders in patients with arterial hypertension and diabetes type 2. – 2021.
14. Alisherovna K. M. et al. Study of qualityof life indicators in patients with coronary heart disease using the sf-36 questionnaire. – 2022.
15. Alisherovna K. M. et al. Effectiveness of statins in the prevention of ischemic heart disease //Web of Scientist: International Scientific Research Journal. – 2022. – Т. 3. – №. 10. – С. 406-413.

16. Erkinovna K. Z. et al. Correction of complications in chronic heart failure depending on the functional state of the kidneys. – 2022.
17. Alisherovna K. M. et al. Diagnostic Significance Daily Monitoring of Blood Pressure in Young Women (Under 40 Years Old) with Arterial Hypertension //Central Asian Journal of Medical and Natural Science. – 2021. – Т. 2. – №. 5. – С. 461-465.
18. Эргашева М. Т. АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ У ЖЕНЩИН В ПОСТМЕНОПАУЗЕ //Журнал кардиореспираторных исследований,(SI-2). – 2022.
19. Alisherovna K. M. et al. Quality of life of patients with cirrhosis of the liver //Spectrum Journal of Innovation, Reforms and Development. – 2022. – Т. 4. – С. 197-202.
20. Nizamitdinovich K. S. et al. Spinal Injury for Rheumatoid Arthritis //Miasto Przyszłości. – 2023. – Т. 40. – С. 426-432.
21. Alisherovna K. M. et al. MORPHOFUNCTIONAL PARAMETERS OF THE HEART IN WOMEN SUFFERING FROM ESSENTIAL ARTERIAL HYPERTENSION IN POSTMENOPAUSE AND ON THE BACKGROUND OF TREATMENT.
22. Jamshedovna K. D., Tashtemirovna E. M. HOMILADOR AYOLLARDA ARTERIAL GIPERTENZIYA VA CHAP QORINCHA DIASTOLIK DISFUNKTSIYASI XUSUSIYATLARI BAXOLASH //Journal of new century innovations. – 2024. – Т. 53. – №. 3. – С. 25-28.
23. Ярмухамедова С. Х., Камолова Д. ПОКАЗАТЕЛИ РЕМОДЕЛИРОВАНИЯ ЛЕВОГО ЖЕЛУДОЧКА У БОЛЬНЫХ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Zbiór artykułów naukowych recenzowanych. – Т. 106.
24. Xusainova M. A. et al. Postmenopauza davridagi ayollarda arterial gipertenziya //Science and Education. – 2023. – Т. 4. – №. 5. – С. 653-660.
25. Djamshedovna K. D., Alisherovna K. M., Islomovich S. I. ARTERIAL HYPERTENSION IN RHEUMATOID ARTHRITIS //Ta'lim innovatsiyasi va integratsiyasi. – 2024. – Т. 31. – №. 2. – С. 139-145.
26. Islomovich S. I., Alisherovna K. M., Djamshedovna K. D. FACTORS OF OSTEOPOROSIS IN PATIENTS WITH CORONARY HEART DISEASE IN COMBINATION WITH RHEUMATOID ARTHRITIS //Ta'lim innovatsiyasi va integratsiyasi. – 2024. – Т. 31. – №. 2. – С. 132-138.
27. Tashtemirovna E. M., Jamshedovna K. D. FEATURES OF CONNECTION OF PNEUMONIA WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE //Academia Repository. – 2024. – Т. 5. – №. 3. – С. 174-183.
28. Камолова Д. Ж. СТРУКТУРНО-ГЕОМЕТРИЧЕСКИЕ ИЗМЕНЕНИЯ В МИОКАРДЕ И ОСОБЕННОСТИ ДИАСТОЛИЧЕСКОЙ ДИСФУНКЦИИ ЛЕВОГО ЖЕЛУДОЧКА У БЕРЕМЕННЫХ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ //Journal of cardiorespiratory research. – 2022. – Т. 3. – №. 1. – С. 40-43.
29. Djamshedovna K. D. et al. EFFECTIVENESS OF ANTIHYPERTENSIVE. – 2023.

30. Камолова Д. Ж., Эргашева М. Т. Особенности ремоделирования сердца и сосудов у беременных при артериальной гипертензии //Science and Education. – 2023. – Т. 4. – №. 5. – С. 581-588.
31. Djamshedovna K. D. et al. THE EFFECT OF PHARMACOTHERAPY ON THE QUALITY OF LIFE OF PREGNANT WOMEN WITH ARTERIAL HYPERTENSION //World Bulletin of Public Health. – 2023. – Т. 27. – С. 37-41.
32. Tashtemirovna E. M. M., Jamshedovna K. D. Arterial hypertension in postmenopausal women //Eurasian Medical Research Periodical. – 2023. – Т. 17. – С. 74-78.
33. Ярмухамедова С. Х. и др. Особенности геометрии миокарда у больных гипертонической болезнью //Современные технологии: проблемы инновационного развития. – 2019. – С. 273-278.
34. Alisherovna K. M., Djamshedovna K. D., Kayumovna A. S. Evaluate the Quality of Life using the KDQOL-SFTM Questionnaire //Central Asian Journal of Medical and Natural Science. – 2022. – Т. 3. – №. 1. – С. 26-31.
35. Ярмухамедова С. Х., Камолова Д. Ж. Изучение геометрии миокарда у больных гипертонической болезнью по данным эхокардиографии //Достижения науки и образования. – 2019. – №. 12 (53). – С. 76-80.
36. Djamshedovna K. D., Alisherovna K. M. CHANGES IN SOME SYSTEM INDICATORS IN PREGNANT WOMEN WITH GESTOSIS //Spectrum Journal of Innovation, Reforms and Development. – 2024. – Т. 25. – С. 111-115.
37. Alisherovna K. M. et al. Endothelial Dysfunction in Patients with Chronic Heart Failure //Miasto Przyszłości. – 2022. – Т. 30. – С. 218-220.
38. Alisherovna K. M., Djamshedovna K. D. AFTER COVID-19 QUALITY OF LIFE //Spectrum Journal of Innovation, Reforms and Development. – 2024. – Т. 25. – С. 103-110.
39. Alisherovna K. M. et al. PSYCHOSOMATIC FEATURES AND THE LEVEL OF DEPRESSION WITH CHRONIC HEART FAILURE IN PATIENTS WITH ARTERIAL HYPERTENSION AND CORONARY HEART DISEASE //Spectrum Journal of Innovation, Reforms and Development. – 2022. – Т. 7. – С. 89-95.
40. Alisherovna K. M. et al. The Effectiveness of the Original Drug Trimetazidine MV in Patients with Stable Ischemic Heart Disease and Persistent Angina Attacks Against the Background of the Use of Trimetazidine Generics //Miasto Przyszłości. – 2022. – Т. 30. – С. 235-238.